Listenly

What is specialty pharmacy drug spending as a percentage of total plan spend, and how has it grown?

Answered at 2:34 in AH118 - Chemo, Cars, & Where Health Plan Savings May be Hiding, with Brian Cotter · The Astonishing Healthcare Podcast

— questions searchable right now

What is specialty pharmacy drug spending as a percentage of total plan spend, and how has it grown?

Specialty drug spend is now between 55-60% of total pharmacy spend. Pharmacy spend overall represents 25-30% of total plan spend, making specialty drugs a significant and rapidly growing portion of employer healthcare expenditures.

Brian Cotter on The Astonishing Healthcare PodcastAll answers from this podcast →
Full answer and detailsRead the whole answer, key facts and every other question from this episode

In short

Specialty drug spend is now between 55-60% of total pharmacy spend.

Brian Cotter, Founder at Bright Spot Insights · AH118 - Chemo, Cars, & Where Health Plan Savings May be Hiding, with Brian Cotter · The Astonishing Healthcare Podcast · answer at 2:34

Key takeaways

  • Specialty drug spend is now between 55-60% of total pharmacy spend.

Quote to remember

“Assume the data is incorrect until proven otherwise. You need to work through the steps to validate the data before you can start digging in and understanding what price variation you see.”

— Brian Cotter

The full answer · about 1 min

Specialty drug spend is now between 55-60% of total pharmacy spend. Pharmacy spend overall represents 25-30% of total plan spend, making specialty drugs a significant and rapidly growing portion of employer healthcare expenditures.

Key facts

  • Oxaliplatin ASP price dropped from $2,053 in 2012 to $9.40 in Q1 2026—a 99% reduction
  • One hospital listed oxaliplatin at $29,595 compared to Medicare reimbursement under $10
  • Specialty drug spend now represents 55-60% of pharmacy spend
  • Pharmacy spend represents 25-30% of total plan spend
  • 431 drugs had price drops between Q1 2025 and Q1 2026, with drops up to 99%

People, companies and topics mentioned

Bright Spot InsightsMedicareASP (Average Sales Price)J code (J9263 for oxaliplatin/Eloxatin)Oxaliplatin (Eloxatan)Specialty drugs (oncology)Price transparency dataMedical benefit

More answers from this episode

 ·  All answers from The Astonishing Healthcare Podcast →
—
—
0:00
0:00